Genetically modified porcine cells, tissue, and animals with reduced human xenoreactivity and methods of using the same
US-2024271103-A1 · Aug 15, 2024 · US
Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
US9889082B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9889082-B2 |
| Application number | US-201514833470-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2015 |
| Priority date | Jun 16, 2006 |
| Publication date | Feb 13, 2018 |
| Grant date | Feb 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analog or mimetic thereof; and methods of testing for AGA and evaluating therapeutic methods thereof, comprising measuring PGD2 levels.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating androgenetic alopecia (AGA) in a scalp of a subject, comprising the step of contacting said subject with an effective amount of a compound or composition comprising a prostaglandin D2 antagonist, thereby treating AGA in the scalp of the subject. 2. The method of claim 1 , further comprising the step of contacting said subject with a pro-hair growth prostaglandin selected from a prostaglandin E1, a prostaglandin E2, a prostaglandin F2a; or an analogue thereof. 3. A method of treating androgenetic alopecia (AGA) in a scalp of a subject, comprising the step of contacting said subject with an effective amount of a prostaglandin (PG) D receptor (DP receptor) antagonist, thereby treating AGA in the scalp of the subject. 4. The method of claim 1 , wherein said compound or composition decreases a level of a prostaglandin D2 in said scalp. 5. The method of claim 1 , wherein the prostaglandin D2 antagonist is a prostaglandin (PG) D receptor (DP receptor) antagonist. 6. The method of claim 5 , wherein the DP receptor antagonist is a CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells)/DP2 receptor antagonist. 7. The method of claim 3 , wherein the DP receptor antagonist is a CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells)/DP2 receptor antagonist.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for dermatological disorders · CPC title
Preparations for care of the skin · CPC title
Eicosanoids, e.g. leukotrienes {or prostaglandins} · CPC title
Hair cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9889082B2 cover?
- This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of s…
- Who is the assignee on this patent?
- Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification A01K67/0275. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).